These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 25175170)
21. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. May M; Nitzke T; Helke C; Vogler H; Hoschke B Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377 [TBL] [Abstract][Full Text] [Related]
22. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122 [TBL] [Abstract][Full Text] [Related]
23. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma. Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262 [TBL] [Abstract][Full Text] [Related]
24. The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas. Chang CC; Tai CJ; Su TC; Shen KH; Lin SH; Yeh CM; Yeh KT; Lin YM; Jiang MC Ann Diagn Pathol; 2012 Oct; 16(5):362-8. PubMed ID: 22476051 [TBL] [Abstract][Full Text] [Related]
26. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma. Behzatoğlu K; Yörükoğlu K; Demir H; Bal N Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766 [TBL] [Abstract][Full Text] [Related]
27. Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal-like urothelial cells: an immunohistochemical and histopathogenetic study. Mai KT; Hakim SW; Ball CG; Flood TA; Belanger EC Pathol Int; 2014 Aug; 64(8):375-81. PubMed ID: 25143125 [TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Cubilla AL; Shih IeM; Netto GJ Hum Pathol; 2015 May; 46(5):761-6. PubMed ID: 25776029 [TBL] [Abstract][Full Text] [Related]
29. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Margulis V; Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y Clin Cancer Res; 2006 Dec; 12(24):7369-73. PubMed ID: 17189409 [TBL] [Abstract][Full Text] [Related]
30. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Xylinas E; Robinson BD; Kluth LA; Volkmer BG; Hautmann R; Küfer R; Zerbib M; Kwon E; Thompson RH; Boorjian SA; Shariat SF Eur J Surg Oncol; 2014 Jan; 40(1):121-7. PubMed ID: 24140000 [TBL] [Abstract][Full Text] [Related]
32. IMP3 expression in urothelial carcinomas of the urinary bladder. Ozdemir NO; Türk NS; Düzcan E Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424 [TBL] [Abstract][Full Text] [Related]
33. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802 [TBL] [Abstract][Full Text] [Related]
34. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Samaratunga H; Khoo K Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study. Sameh R; Mostafa N; Ramadan M; AbdelRaouf S; Abdelwahab K J Histotechnol; 2022 Mar; 45(1):21-28. PubMed ID: 34493171 [TBL] [Abstract][Full Text] [Related]
36. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881 [TBL] [Abstract][Full Text] [Related]
37. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder. Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270 [TBL] [Abstract][Full Text] [Related]
38. Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. Minner S; De Silva C; Rink M; Dahlem R; Chun F; Fisch M; Höppner W; Wagner W; Bokemeyer C; Terracciano L; Simon R; Sauter G; Wilczak W Pathology; 2012 Aug; 44(5):448-52. PubMed ID: 22772340 [TBL] [Abstract][Full Text] [Related]
39. Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. Dugas SG; Müller DC; Le Magnen C; Federer-Gsponer J; Seifert HH; Ruiz C; Savic Prince S; Vlajnic T; Zellweger T; Mertz KD; Bacon JVW; Wyatt AW; Rentsch CA; Bubendorf L Cancer Cytopathol; 2019 Sep; 127(9):578-585. PubMed ID: 31386310 [TBL] [Abstract][Full Text] [Related]